These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 24048239)

  • 1. Confidence in generic drug substitution.
    Lionberger R; Jiang W; Huang SM; Geba G
    Clin Pharmacol Ther; 2013 Oct; 94(4):438-40. PubMed ID: 24048239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A generic drug primer: regulatory aspects and scientific concepts.
    Henderson JD; White GL
    Mil Med; 1998 Apr; 163(4):193-7. PubMed ID: 9575760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug Information Association Pharmacovigilance and Risk Management Strategies 2017: Overview of the Generic Drug Program and Surveillance.
    Chazin HD; Peters JR; Catterson DM; Osterhout JL; Forsyth LM; Lee JE; Kim EK; Feibus KB
    Ther Innov Regul Sci; 2019 Mar; 53(2):249-253. PubMed ID: 29742934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioavailability and bioequivalence: an FDA regulatory overview.
    Chen ML; Shah V; Patnaik R; Adams W; Hussain A; Conner D; Mehta M; Malinowski H; Lazor J; Huang SM; Hare D; Lesko L; Sporn D; Williams R
    Pharm Res; 2001 Dec; 18(12):1645-50. PubMed ID: 11785681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative assessment of the switchability of generic products.
    Karalis V; Bialer M; Macheras P
    Eur J Pharm Sci; 2013 Nov; 50(3-4):476-83. PubMed ID: 23981332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk-Based Bioequivalence Recommendations for Antiepileptic Drugs.
    Li Z; Fang L; Jiang W; Kim MJ; Zhao L
    Curr Neurol Neurosci Rep; 2017 Sep; 17(11):82. PubMed ID: 28929357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generic substitution: issues for problematic drugs.
    Henderson JD; Esham RH
    South Med J; 2001 Jan; 94(1):16-21. PubMed ID: 11213935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
    Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
    Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioequivalence and other unresolved issues in generic drug substitution.
    Meredith P
    Clin Ther; 2003 Nov; 25(11):2875-90. PubMed ID: 14693311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Product selection, bioequivalence, and therapeutic equivalence: the generic drug market.
    Halperin JA
    Drug Inf J; 1983; 17(2):73-6. PubMed ID: 10263719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: A field test of the FDA bioequivalence standard.
    Ting TY; Jiang W; Lionberger R; Wong J; Jones JW; Kane MA; Krumholz A; Temple R; Polli JE
    Epilepsia; 2015 Sep; 56(9):1415-24. PubMed ID: 26201987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is Bioequivalence a Sufficient Measure of Equivalence?
    Holman A
    J Leg Med; 2019; 39(3):247-261. PubMed ID: 31626574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of the safety of generic drugs.
    Dighe SV
    Transplant Proc; 1999 May; 31(3A Suppl):23S-24S. PubMed ID: 10330955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulating Generic Ophthalmologic Drug Bioequivalence-Envisioning Accessibility for Patients.
    Luke MC; Kozak D
    J Ocul Pharmacol Ther; 2021 Apr; 37(3):157-161. PubMed ID: 33332225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implementation of a reference-scaled average bioequivalence approach for highly variable generic drug products by the US Food and Drug Administration.
    Davit BM; Chen ML; Conner DP; Haidar SH; Kim S; Lee CH; Lionberger RA; Makhlouf FT; Nwakama PE; Patel DT; Schuirmann DJ; Yu LX
    AAPS J; 2012 Dec; 14(4):915-24. PubMed ID: 22972221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addressing the Regulatory and Scientific Challenges with Generic Orally Inhaled Drug Products.
    Newman B; Witzmann K
    Pharmaceut Med; 2020 Apr; 34(2):93-102. PubMed ID: 32112304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Critical therapeutic categories: a contraindication to generic substitution?
    Colaizzi JL; Lowenthal DT
    Clin Ther; 1986; 8(4):370-9. PubMed ID: 3731208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physicians' Trust in the FDA's Use of Product-Specific Pathways for Generic Drug Approval.
    Kesselheim AS; Eddings W; Raj T; Campbell EG; Franklin JM; Ross KM; Fulchino LA; Avorn J; Gagne JJ
    PLoS One; 2016; 11(10):e0163339. PubMed ID: 27768700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Switching Patterns in FDA's Sentinel System: A New Tool to Assess Generic Drugs.
    Gagne JJ; Popovic JR; Nguyen M; Sandhu SK; Greene P; Izem R; Jiang W; Wang Z; Zhao Y; Petrone AB; Wagner AK; Dutcher SK
    Drug Saf; 2018 Dec; 41(12):1313-1323. PubMed ID: 30120741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Bioequivalence Approach for Generic Narrow Therapeutic Index Drugs: Evaluation of the Reference-Scaled Approach and Variability Comparison Criterion.
    Jiang W; Makhlouf F; Schuirmann DJ; Zhang X; Zheng N; Conner D; Yu LX; Lionberger R
    AAPS J; 2015 Jul; 17(4):891-901. PubMed ID: 25840883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.